In the News
May 5, 2022
- Source: Pink Sheet
Lisa Dwyer comments on the House legislation renewing the U.S. Food and Drug Administration’s user fee programs that would undo negative court rulings against the agency and reinstate its policies on orphan drug exclusivity and the designation of contrast agents as drugs